Pharmacokinetic and imaging evaluation of (99m)Tc-HBIDP as a potential bone imaging agent

Developing novel superior bone-seeking radiopharmaceutical for the detection of malignant bone lesions could further improve the diagnostic value of routine bone scanning and shorten the interval between injection and imaging. In order to further evaluate the bone imaging efficiency of (99m)Tc-HBIDP (1-hydroxy-2-(1-butyl-imidazol-2-yl)-ethane-1,1-diphosphonic acid), the pharmacokinetic in mice and single photon emission computed tomography (SPECT) bone scanning in rabbit for (99m)Tc-HBIDP was investigated. Kinetics of blood clearance showed that the distribution half-life (T(1/2a)) and elimination half-life (T(1/2 β)) of (99m)Tc-HBIDP are 2.73 and 24.87 min, respectively. Excellent bone images can be obtained at 1 h post injection with SPECT bone scanning, which is clearer and quicker than (99m)Tc-ZL (zoledronate) and (99m)Tc-MDP (methylenediphosphonate). All results indicate that (99m)Tc-HBIDP holds great potential as a novel improved bone imaging agent.